Why Pakistan’s Pharmaceutical Exports Lag Behind and How to Fix It– Asrar Qureshi’s Blog Post #1124

Pakistan’s pharmaceutical exports are notably low despite having a robust industry, with challenges including inadequate investment in facilities, lack of international certifications, inconsistent compliance with quality standards, and insufficient market intelligence. Strategic reforms, including regulatory improvements and investment in workforce development, are essential for enhancing exports and achieving global competitiveness.
Share
View Post

Formation of PharmEx Pakistan – Too Late, Too Little? – Asrar Qureshi’s Blog Post #1123

The Ministry of Commerce in Pakistan is launching PharmEx Pakistan to boost pharmaceutical exports, aiming to increase annual exports from $700 million to $3 billion. This public-private initiative, modeled after India’s Pharmexcil, seeks to enhance regulatory compliance and global visibility for Pakistani pharmaceuticals, while facing challenges in international competitiveness.
Share
View Post

Colossal Wrongdoings by Big Pharma – Ranbaxy Scandal – Asrar Qureshi’s Blog Post #1093

The Ranbaxy scandal illustrates significant fraud within a major Indian pharmaceutical company that misled regulatory bodies and compromised drug safety. Whistleblower Dinesh Thakur’s revelations led to a $500 million settlement, exposing flaws in oversight and raising questions about generics. It’s a vital lesson on ethical standards and regulatory vigilance in the industry.
Share